Cornell University

Tri-institutional Therapeutics Discovery Institute

John D Ginn

Toshihiro Imaeda

Tzu-Tshin Wong

Kenjiro Sato

Rei Okamoto

Takafumi Yukawa

Kazuyoshi Aso

Akinori Toita

Wenhu Zhan

Trevor Morgan

Ryoma Hara

Laura Kirkman

Masanori Kawasaki

Gang Herbert Lin

Carl F Nathan

Michael Andrew Foley

The compounds of the present invention are represented by the following compounds having Formula I and Formula (I′): where the substituents R, R, R, R, R, R, R', R″, X, Y, and Z are as defined herein and where the substituents R, R, R, R, R, R', R″, X, Y, and Z are as defined herein. These compounds are used in the treatment of bacterial infections, parasite infections, fungal infections, cancer, immunologic disorders, autoimmune disorders, neurodegenerative diseases and disorders, inflammatory disorders, or muscular dystrophy or for providing immunosuppression for transplanted organs or tissues.

Macrocyclic compounds as proteasome inhibitors

The compounds of the present invention are represented by the following compounds having Formula I and Formula (I'): where the substituents R, R, R, R, R, R, R&#x2032;, R&#x2033;, X, Y, and Z are as defined herein and where the substituents R, R, R, R, R, R&#x2032;, R&#x2033;, X, Y, and Z are as defined herein. These compounds are used in the treatment of bacterial infections, parasite infections, fungal infections, cancer, immunologic disorders, autoimmune disorders, neurodegenerative diseases and disorders, inflammatory disorders, or muscular dystrophy or for providing immunosuppression for transplanted organs or tissues.

Growing community of inventors

New Milford, CT, United States of America

John D Ginn